Laxatract 667 mg/ml oral solution

Authorised

- Lactulose, liquid

Product identification

Medicine name:
Laxatract 667 mg/ml oral solution
Laxatract 667 mg/ml saft handa hundum og köttum

Active substance:
Lactulose, liquid

Target species:
Dog
Cat

Route of administration:
Oral use

Product details

Active substance and strength:
Lactulose, liquid
667.00 milligram(s) / 1.00 millilitre(s)

Pharmaceutical form:
Syrup

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QA06AD11

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Iceland

Package description:
HDPE bottle closed with a (LDPE) syringe inlay and a (HDPE) cap. Cardboard box of 1 bottle of 50 ml with a 5ml oral syringe.
HDPE bottle closed with a (LDPE) syringe inlay and a (HDPE) cap. Cardboard box of 1 bottle of 125 ml with a 5ml oral syringe.
HDPE bottle closed with a (LDPE) syringe inlay and a cap (PP). Cardboard box of 1 bottle of 325 ml with a 10ml oral syringe.

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Dechra Regulatory B.V.

Marketing authorisation date:
20/12/2018

Manufacturing sites for batch release:
Feramed B.V.

Responsible authority:
Icelandic Medicines Agency

Authorisation number:
IS/2/18/012/01

Date of authorisation status change:
20/12/2018

Reference member state:
Netherlands

Procedure number:
NL/V/0241/001

Concerned member states:
Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet